Big Pharma Needs New Drugs. China Has Them

Pharmaceutical companies based in the United States are licensing and acquiring drug candidates from Chinese biotech firms at an accelerating rate. Bloomberg reported that major U.S. pharmaceutical manufacturers have signed multiple licensing agreements with Chinese developers over the past two years to bring drugs into their pipelines. The shift reflects access to a large pool of early-stage drug candidates and lower development costs compared to domestic research programs.

Next story